Compare Citius Pharmaceuticals Inc (CTXR) vs Global Payments Inc (GPN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Global Payments Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.77 (market cap $20.01M), while Global Payments Inc trades at $88.53 (market cap $22.72B). The key difference: Global Payments Inc is far larger — about 1135.4× Citius Pharmaceuticals Inc's market cap, and Global Payments Inc pays a 1.16% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | GPN | |
|---|---|---|
Market Cap | $20.01M | $22.72B |
Sector | Health | Industrials |
52-Week High | $1.82 | $90.01 |
52-Week Low | $0.48 | $62.47 |
Enterprise Value | $16.23M | $40.87B |
Dividend Yield | — | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.7554, up 11.58% today, with a bullish technical signal from moving averages. The company reported a net loss of $37.43M for 2025, with a negative net income margin of -823.34%, but shows revenue growth from its LYMPHIR launch. Recent news highlights commercial expansion and positive clinical data presentations at ASCO 2026.
The outlook is speculative; analyst consensus is strongly bullish (83.3% Buy), but high cash burn and consistent earnings misses pose significant risks. Investment potential hinges on successful commercialization of LYMPHIR to achieve profitability.
Global Payments (GPN) trades at $88.65, up 2.93% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 63.91% gross margin but negative net income margin and ROE. Recent Q2 2026 EPS of $3.46 beat estimates, though revenue guidance was trimmed. Analyst consensus is a Buy with a $96.67 target.
GPN offers upside to analyst targets but faces risks from margin pressure and competitive fintech landscape. Debt-to-asset ratio rose to 41.57% in 2025, increasing financial leverage concerns. Investment appeal hinges on execution of the Genius platform strategy amid economic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Global Payments Inc
Global Payments is a leading provider of payment processing and software solutions and focuses on serving small and midsize merchants. The company operates in 30 countries and generates about one fourth of its revenue from outside North America, primarily in Europe and Asia. In 2019, Global Payments merged with Total System Services in an all-stock deal that gave Total System Services shareholders 48% of the combined company's shares.
Read more on GPN →
